Matthew Butler, MD
Hematology & Oncology · San Antonio, TXNPI 1013297167
Payments from drug & device makers
Across 119 payments — averaging $4411.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$218K
- Otsuka Pharmaceutical Co., Ltd.$96K
- E.r. Squibb & Sons, L.L.C.$76K
- GSK$58K
- Janssen Research & Development, LLC$40K
- Blueprint Medicines Corporation$30K
- plus $7K from 16 others
What the payments were for
- Consulting fees$6,71516%
- Speaking & faculty fees$30,55075%
- Travel & lodging$9452%
- Food & beverage$2,3576%
- Education$1350%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 8 | $218,275 |
| Otsuka Pharmaceutical Co., Ltd. | 25 | $95,816 |
| E.r. Squibb & Sons, L.L.C. | 4 | $75,656 |
| GSK | 36 | $57,737 |
| Janssen Research & Development, LLC | 12 | $40,419 |
| Blueprint Medicines Corporation | 8 | $29,760 |
| Beigene USA, Inc. | 2 | $2,280 |
| Johnson & Johnson | 3 | $1,731 |
| Pharmaessentia USA Corporation | 3 | $1,175 |
| AstraZeneca | 2 | $617 |
| Beigene, Ltd. | 1 | $525 |
| Sanofi | 3 | $346 |
| Karyopharm Therapeutics Inc. | 2 | $302 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $100 |
| Tesaro, Inc. | 1 | $59 |
| Novartis | 2 | $50 |
| Inari Medical, Inc. | 1 | $33 |
| Amgen | 1 | $29 |
| Genentech USA, Inc. | 1 | $20 |
| Merck | 1 | $18 |
| Pfizer | 1 | $17 |
| Dova Pharmaceuticals | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$524,982 in reported general payments places this provider in the 80th percentile of 838 hematology & oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 181 | $3,300,457 |
| Lenalidomide | 208 | $2,670,808 |
| PomalystPomalidomide | 86 | $1,862,555 |
| XpovioSelinexor | 28 | $898,935 |
| NinlaroIxazomib Citrate | 39 | $525,413 |
| PromactaEltrombopag Olamine | 14 | $469,725 |
| ImbruvicaIbrutinib | 31 | $459,219 |
| OnuregAzacitidine | 14 | $361,336 |
| CalquenceAcalabrutinib Maleate | 37 | $319,830 |
| BrukinsaZanubrutinib | 26 | $294,044 |
| VenclextaVenetoclax | 35 | $258,028 |
| TasignaNilotinib Hcl | 14 | $249,466 |
| EliquisApixaban | 19 | $20,270 |
| ValacyclovirValacyclovir Hcl | 222 | $5,723 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 74 | $2,341 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $218,275 | $3,300,457181 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst, Onureg | $75,656 | $2,223,891100 claims |
| Karyopharm Therapeutics Inc.Xpovio | $302 | $898,93528 claims |
| NovartisPromacta, Tasigna | $50 | $719,19028 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro | $100 | $525,41339 claims |
| AstraZenecaCalquence | $617 | $319,83037 claims |
| Beigene USA, Inc.Brukinsa | $2,280 | $294,04426 claims |
| PfizerEliquis | $17 | $20,27019 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 838 hematology & oncology providers in Texas.
Other hematology & oncology in San Antonio
- Kyriakos PapadopoulosSan Antonio$18.5M
- Drew RascoSan Antonio$14.1M
- David SommerhalderSan Antonio$10.4M
- Emmalind AponteSan Antonio$4.4M
- Manuel SantiagoSan Antonio$3.9M
- Paul ShaughnessySan Antonio$3.7M
- Ildefonso Rodriguez RiveraSan Antonio$2.7M
- Sharon WilksSan Antonio$2.5M
- Elias JabbourHouston$264.1M
- Luhua WangHouston$79.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.